Skip to main content

Table 3 Overall efficacy and response to treatment with nal-IRI + 5-FU/LV

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

  N = 56 (%)
PFS (median, mo) 2.9
OS (median, mo) 5.3
Response rate
 Partial response 3 (5)
 Stable disease 23 (41)
 Progressive disease 23 (41)
 Not evaluabe 7 (13)
CA 19–9 response (maximal response/baseline)
  > 1 19 (34)
 0.5 to 1 15 (27)
  < 0.5 10 (18)
 not evaluable 10 (18)
 not measurable 2 (4)
Advanced disease, OS (median, mo)
 All 24.2
 Sequence 1 25.5
 Sequence 2 23.0
 nab-P + Gem → Gem/Cap → nal-IRI + 5-FU/LV 28.6
 other 23.0